Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Schizophrenia Research
Hua JinDilip V Jeste

Abstract

Many adverse effects of atypical antipsychotic treatment are associated with antagonism of monoamine receptors; however, data indicate that important metabolic effects, such as hypertriglyceridemia and impairment in glucose/insulin homeostasis, may not be related to these mechanisms, leading investigators to explore alternative hypotheses. Promising candidates include a possible impact of antipsychotics on peptide hormonal regulators of metabolic control such as leptin, ghrelin, and adiponectin. The purpose of this review is to summarize recent data on changes in these hormones during atypical antipsychotic treatment. A Medline search was performed for papers published from January 1999 to January 2007 using key words antipsychotic, atypical antipsychotic, and individual atypical antipsychotic drug names cross-referenced with leptin, ghrelin, and adiponectin. The bulk of the published work focused on changes in body weight and serum leptin, with far less data on ghrelin, and adiponectin, and nonweight metabolic changes. Leptin changes were directly related to a medication's weight gain liability, with no added antipsychotic effects on leptin signaling. Conflicting results emerged for the other markers, but all three long-term s...Continue Reading

References

Apr 16, 1996·Biochemical and Biophysical Research Communications·K MaedaK Matsubara
Mar 10, 1998·Molecular Psychiatry·T BrömelJ Hebebrand
Mar 27, 1999·Biochemical and Biophysical Research Communications·Y AritaY Matsuzawa
Nov 1, 2000·Nature·M TschöpM L Heiman
May 10, 2001·The Journal of Clinical Endocrinology and Metabolism·C WeyerP A Tataranni
Jul 4, 2001·The British Journal of Psychiatry : the Journal of Mental Science·A HerránJ L Vázquez-Barquero
Oct 2, 2001·The American Journal of Psychiatry·U EderW W Fleischhacker
Dec 19, 2001·The American Journal of Medicine·E KollerG Dubitsky
Jan 5, 2002·The Journal of Clinical Psychiatry·T Baptista, S Beaulieu
Jul 20, 2002·Pharmacotherapy·Elizabeth A Koller, P Murali Doraiswamy
Aug 13, 2002·Journal of Clinical Psychopharmacology·Palmiero MonteleoneMario Maj
Oct 31, 2002·Nutrition Reviews·Jeffrey M Friedman
Nov 6, 2002·The Journal of Clinical Psychiatry·Donna A WirshingWilliam C Wirshing
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
May 21, 2003·The Journal of Clinical Psychiatry·Murad AtmacaBilal Ustundag
May 29, 2003·Current Pharmaceutical Design·Tamas L HorvathMatthias H Tschöp
Jun 25, 2003·Pharmacotherapy·Elizabeth A KollerBruce S Schneider
Jul 10, 2003·Annals of the New York Academy of Sciences·Rachell L Batterham, Stephen R Bloom
Aug 16, 2003·Journal of Clinical Psychopharmacology·Roger S McIntyreSidney H Kennedy
Aug 19, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Berna Binnur KivircikSena Yeşil
Sep 5, 2003·The New England Journal of Medicine·Judith Korner, Rudolph L Leibel
Oct 11, 2003·Psychopharmacology·Takashi TogoKenji Kosaka
Jan 13, 2004·Human Psychopharmacology·Murad AtmacaNulufer Kilic
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Feb 7, 2004·Current Diabetes Reports·Roopa Sathyaprakash, Robert R Henry

❮ Previous
Next ❯

Citations

Nov 28, 2013·Pharmacogenomics·Amy C C Kao, Daniel J Müller
Feb 13, 2009·Der Nervenarzt·D J MüllerA Heinz
Mar 16, 2016·Neural Plasticity·Vanja DuricLi-Lian Yuan
Jun 7, 2011·Comprehensive Psychiatry·Mounir H Fawzi, Mohab M Fawzi
May 4, 2011·The Psychiatric Clinics of North America·Alana IglewiczDilip V Jeste
Apr 23, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Martien WampersMarc De Hert
Dec 28, 2010·Trends in Molecular Medicine·Christoph U CorrellAnil K Malhotra
Nov 26, 2009·Pharmacology & Therapeutics·Gavin P Reynolds, Shona L Kirk
Jun 30, 2009·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Aditi MathurJun Wei
Jul 15, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Francesco BartoliGiuseppe Carrà
Jul 31, 2013·Neuroscience Research·Yoichiro TakayanagiWilliam W Eaton
May 28, 2014·Journal of Chemical Neuroanatomy·Jeanette C Valleau, Elinor L Sullivan
Nov 9, 2010·Behavioural Brain Research·Katrina Weston-GreenChao Deng
May 25, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ruili DangPing Xu
Dec 3, 2014·Psychoneuroendocrinology·Dirk Alexander Wittekind, Michael Kluge
Aug 21, 2013·Psychoneuroendocrinology·Qingsheng ZhangXu-Feng Huang
Oct 7, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·J-P KlemettiläE Leinonen
Apr 2, 2015·Psychoneuroendocrinology·Francesco BartoliGiuseppe Carrà
Jan 20, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Sasi NeelamekamJimmy Lee
Dec 17, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mong-Liang LuVincent Chin-Hung Chen
Apr 16, 2011·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Cristina CuerdaCelso Arango
May 20, 2014·Psychiatry Research·Jari-Pekka KlemettiläEsa Leinonen
Dec 20, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Pedro GonçalvesFátima Martel
May 23, 2016·European Child & Adolescent Psychiatry·Inmaculada BaezaJosefina Castro-Fornieles
Jun 3, 2016·Psychopharmacology·Louise BenarrochMargaret K Hahn
Jun 30, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Deniz Sezlev-BilecenTulin Yanik
Sep 24, 2013·Neuroscience Letters·Somayeh DashtiAli Shahbazi
Jan 4, 2017·European Psychiatry : the Journal of the Association of European Psychiatrists·M SykJ L Cunningham
Sep 30, 2016·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Kamini VasudevUte I Schwarz
Apr 20, 2017·Journal of Child and Adolescent Psychopharmacology·Ayush PatelHua Chen
Feb 16, 2017·European Psychiatry : the Journal of the Association of European Psychiatrists·C TheleritisS Smith
Apr 5, 2012·Journal of Psychopharmacology·Brian E LeonardAye Mu Myint
Nov 23, 2017·Frontiers in Psychiatry·Milica Milovan BorovcaninMiodrag L Lukic
Dec 7, 2017·Frontiers in Neuroscience·Jiezhong ChenChao Deng
Dec 30, 2014·World Journal of Psychiatry·Andrzej WędrychowiczPrzemysław J Tomasik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.